| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Xia Zhang, Jie Yang, Hong-Ling Ha. [Visceral Vein Thrombosis of Myeloproliferative Neoplasm --Review]. Zhongguo shi yan xue ye xue za zhi. vol 30. issue 5. 2022-10-08. PMID:36208278. |
patients with non-cirrhotic svt need to detect mpn mutation, while the detection of calr or mpl mutation needs to be combined with clinical judgment. |
2022-10-08 |
2023-08-14 |
Not clear |
| Vitor Leonardo Bassan, Gabriel Dessotti Barretto, Felipe Campos de Almeida, Patrícia Vianna Bonini Palma, Larissa Sarri Binelli, João Paulo Lettieri da Silva, Caroline Fontanari, Ricardo Cardoso Castro, Lorena Lôbo de Figueiredo Pontes, Fabiani Gai Frantz, Fabíola Attié de Castr. Philadelphia-negative myeloproliferative neoplasms display alterations in monocyte subpopulations frequency and immunophenotype. Medical oncology (Northwood, London, England). vol 39. issue 12. 2022-09-29. PMID:36175590. |
philadelphia-negative myeloproliferative neoplasms (mpn) are clonal hematological diseases associated with driver mutations in jak2, calr, and mpl genes. |
2022-09-29 |
2023-08-14 |
Not clear |
| Saumya E Samaraweera, Tatjana Geukens, Debora A Casolari, Tran Nguyen, Caitlyn Sun, Sheree Bailey, Sarah Moore, Jinghua Feng, Andreas W Schreiber, Wendy T Parker, Anna L Brown, Carolyn Butcher, Peter G Bardy, Michael Osborn, Hamish S Scott, Dipti Talaulikar, Carolyn S Grove, Christopher N Hahn, Richard J D'Andrea, David M Ros. Novel modes of MPL activation in triple-negative myeloproliferative neoplasms. Pathology. 2022-08-28. PMID:36031433. |
to identify potential drivers that might explain the clinical phenotype, we used an extended sequencing panel to characterise a cohort of 44 previously diagnosed triple-negative mpn patients for canonical mutations in jak2, mpl and calr at low variant allele frequency (found in 4/44 patients), less common variants in the jak-stat signalling pathway (12 patients), or other variants in recurrently mutated genes from myeloid malignancies (18 patients), including hotspot variants of potential clinical relevance in eight patients. |
2022-08-28 |
2023-08-14 |
Not clear |
| Irene Pastor-Galán, Iván Martín, Blanca Ferrer, Juan-Carlos Hernández-Bolud. Impact of molecular profiling on the management of patients with myelofibrosis. Cancer treatment reviews. vol 109. 2022-07-15. PMID:35839532. |
constitutive signaling through the jak-stat pathway plays a fundamental role in its pathogenesis, generally due to activating mutations of jak2, calr and mpl genes (i.e., the mpn driver mutations), present in most mf patients. |
2022-07-15 |
2023-08-14 |
Not clear |
| Maira da Costa Cacemiro, Juçara Gastaldi Cominal, Luiz Miguel Pereira, Maria Gabriela Berzoti-Coelho, Giovana Michelassi Berbel, Luciana Baroni, Tathiane Malta, Raquel Tognon, Natalia de Souza Nunes, Elizabeth Xisto Souto, Lorena Lobo de Figueiredo-Pontes, Ana Patricia Yatsuda, Fabíola Attié de Castr. Hippo pathway-related genes expression is deregulated in myeloproliferative neoplasms. Medical oncology (Northwood, London, England). vol 39. issue 5. 2022-05-22. PMID:35599283. |
mpn patients may present driver mutations in jak2, mpl, and calr genes, which are essential to describe the molecular mechanisms of mpn pathogenesis. |
2022-05-22 |
2023-08-13 |
Not clear |
| Akihiko Goto. Philadelphia chromosome-negative myeloproliferative neoplasms: clinical aspects and treatment options. International journal of hematology. 2022-04-10. PMID:35397744. |
clinical studies of philadelphia chromosome-negative myeloproliferative neoplasms (mpn) have progressed greatly with the discovery of mutations in three driver genes: jak2, mpl, and calreticulin. |
2022-04-10 |
2023-08-13 |
Not clear |
| Yanjie Li, Hui Gao, Hongyan Dong, Weiwei Wang, Zhengqing Xu, Guozhang Wang, Yahui Liu, Haiyang Wang, Wen Ju, Jianlin Qiao, Kailin Xu, Chunling Fu, Lingyu Zen. PEDF reduces malignant cells proliferation and inhibits the progression of myelofibrosis in myeloproliferative neoplasms. Biochemical pharmacology. 2022-03-23. PMID:35318038. |
in this study, we found that pedf expression was down-regulated in mpn patients and mpl |
2022-03-23 |
2023-08-13 |
Not clear |
| Alice Moncada, Alessandro Pancrazz. Lab tests for MPN. International review of cell and molecular biology. vol 366. 2022-02-14. PMID:35153004. |
the investigation on driver genes for mpn ph neg forms includes activity for erythroid forms such as polycythemia vera (test jak2v617f and jak2 exon 12), for non-erythroid forms such as essential thrombocythemia and myelofibrosis (test jak2v617f, calr exon 9, mpl exon 10), for "atypical" ones such as mastocytosis (ckit d816v test) and for hypereosinophilic syndrome (fip1l1-pdgfralpha test). |
2022-02-14 |
2023-08-13 |
Not clear |
| Fiorella Schischli. Transcriptional configurations of myeloproliferative neoplasms. International review of cell and molecular biology. vol 366. 2022-02-14. PMID:35153005. |
this led to identification of major mpn driver genes, jak2, mpl and calr. |
2022-02-14 |
2023-08-13 |
Not clear |
| Sergiu Pasca, Helen T Chifotides, Srdan Verstovsek, Prithviraj Bos. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN. International review of cell and molecular biology. vol 366. 2022-02-14. PMID:35153007. |
herein, we comprehensively review the impact of the three signaling driver mutations (jak2 v617f, calr exon 9 indels, mpl w515k/l) that constitutively activate the jak/stat pathway, and of the other somatic non-driver mutations (epigenetic, mrna splicing, transcriptional regulators, and mutations in signal transduction genes) that cooperatively or independently promote mpn progression and leukemic transformation. |
2022-02-14 |
2023-08-13 |
Not clear |
| Garima Pandey, Andrew T Kuykendall, Gary W Reuthe. JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation. Blood cancer journal. vol 12. issue 1. 2022-01-27. PMID:35082276. |
the philadelphia chromosome negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocytosis, and myelofibrosis, are driven by hyper activation of the jak2 tyrosine kinase, the result of mutations in three mpn driving genes: jak2, mpl, and calr. |
2022-01-27 |
2023-08-13 |
mouse |
| Jiale Ma, Shan Chen, Yanqing Huang, Jie Zi, Jinlong Ma, Zheng G. Philadelphia-positive acute lymphoblastic leukemia in a case of MPL p.(W515L) variant essential thrombocythemia: case report and literature review. Platelets. 2021-12-13. PMID:34895021. |
although relapsed eventually, this is still a very rare case of simultaneous presence of two cytogenetics abnormalities and evolution of mpl p.(w515l) variant et to ph+all and may provide evidence to illustrate the clonal relationship of mpn and post-mpn all. |
2021-12-13 |
2023-08-13 |
Not clear |
| Jerry L Spiva. Advances in polycythemia vera and lessons for acute leukemia. Best practice & research. Clinical haematology. vol 34. issue 4. 2021-12-07. PMID:34865702. |
the myeloproliferative neoplasms (mpn), polycythemia vera (pv), essential thrombocytosis and primary myelofibrosis, are an unusual group of myeloid neoplasms, which arise in a pluripotent hematopoietic stem cell (hsc) due to gain of function driver mutations in the jak2, calr and mpl genes that constitutively activate jak2, the cognate tyrosine kinase of the type 1 hematopoietic growth factor (hgf) receptors. |
2021-12-07 |
2023-08-13 |
Not clear |
| Chunqing Wang, Xueting Hu, Yan Wan, Shujin Wang, Kunming Qi, Yanjie Li, Jianlin Qiao, Lingyu Zeng, Zhenyu Li, Chunling Fu, Kailin X. The Synergistic Inhibitory Effect of Combining MK-2206 and AZD 6244 in MARIMO Cells Harboring a Calreticulin Gene Mutation. Chemotherapy. vol 66. issue 5-6. 2021-12-03. PMID:34666331. |
somatic mutations in the calreticulin (calr) gene occur in most myeloproliferative neoplasm (mpn) patients who lack janus kinase 2 or thrombopoietin receptor (mpl) mutations, but the molecular pathogenesis of mpn with mutated calr is unclear, which limited the further treatment for calr gene mutant patients. |
2021-12-03 |
2023-08-13 |
Not clear |
| Paola Guglielmelli, Laura Calabres. The MPL mutation. International review of cell and molecular biology. vol 365. 2021-12-03. PMID:34756243. |
myeloproliferative neoplasms (mpn) patients share driver mutations in jak2, mpl or calr genes leading to the activation of the thrombopoietin receptor (tpor) and downstream signaling pathways. |
2021-12-03 |
2023-08-13 |
Not clear |
| Paola Guglielmelli, Laura Calabres. The MPL mutation. International review of cell and molecular biology. vol 365. 2021-12-03. PMID:34756243. |
against this molecular background, tpor is a key actor in the mpn development and mpl mutations are of major relevance to fully elucidate the molecular mechanisms underlying the clinical manifestations of mpn and to arrange novel therapeutic strategies aiming to disrupt the dysegulated signaling cascade. |
2021-12-03 |
2023-08-13 |
Not clear |
| Paola Guglielmelli, Laura Calabres. The MPL mutation. International review of cell and molecular biology. vol 365. 2021-12-03. PMID:34756243. |
this chapter will focus on the role mpl in the pathogenesis of mpn and in familial thrombocytosis and will review these different subtypes of somatic and germline genetic variants by dissecting how they impact clinical phenotype. |
2021-12-03 |
2023-08-13 |
Not clear |
| Jan Stetka, Radek C Skod. Mouse models of myeloproliferative neoplasms for pre-clinical testing of novel therapeutic agents. Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia. vol 165. issue 1. 2021-11-03. PMID:33542546. |
myeloproliferative neoplasms (mpn), are clonal hematopoietic stem cell (hsc) disorders driven by gain-of-function mutations in jak2 (jak2-v617f), calr or mpl genes. |
2021-11-03 |
2023-08-13 |
mouse |
| Simona Stivala, Sara C Meye. Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms. Cancers. vol 13. issue 20. 2021-10-26. PMID:34680185. |
somatic mutations in jak2, calreticulin, and mpl genes drive myeloproliferative neoplasms (mpn), and recent technological advances have revealed a heterogeneous genomic landscape with additional mutations in mpn. |
2021-10-26 |
2023-08-13 |
Not clear |
| Chi Young Ok, Kevin T Trowell, Kyle G Parker, Karen Moser, Olga K Weinberg, Heesun J Rogers, Kaaren K Reichard, Tracy I George, Eric D Hsi, Carlos E Bueso-Ramos, Wayne Tam, Attilio Orazi, Adam Bagg, Daniel A Arber, Robert P Hasserjian, Sa A Wan. Chronic myeloid neoplasms harboring concomitant mutations in myeloproliferative neoplasm driver genes (JAK2/MPL/CALR) and SF3B1. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. vol 34. issue 1. 2021-10-25. PMID:32694616. |
jak2, calr, and mpl are myeloproliferative neoplasm (mpn)-driver mutations, whereas sf3b1 is strongly associated with ring sideroblasts (rs) in myelodysplastic syndrome (mds). |
2021-10-25 |
2023-08-13 |
Not clear |